The off-label use of botulinum toxin type-A (BoNT-A) in treating rosacea seems encouraging, but the evidence is still lacking regarding its efficacy and safety. This study was conducted to summarize the evidence regarding the efficacy and safety of BoNT-A in the treatment of rosacea patients. A comprehensive literature search was conducted in several databases, and 17 studies were included. Before-after and splitface comparisons showed that BoNT-A significantly alleviated the symptoms of facial erythema and flushing and improved the patient's quality of life/satisfaction. However, the symptoms recurred three to six months post-injection, requiring repeated treatments in some patients. The pooled rates of post-injection localized erythema, ecchymosis, and facial muscle affection represented 24.6%, 5.1%, and 4.3%, respectively. BoNT-A seems to be effective in alleviating the symptoms of rosacea with a low rate of adverse events. However, the recurrence of the symptoms a few months after the injection requires repeated sessions, which may raise cost-effectiveness issues. Large-scale clinical trials are required to confirm the effectiveness and define the optimal dosing regimen and the rate of recurrence. Future studies should allow for an adequate follow-up after the treatment, with repeated measurements of the outcomes.
1 July 2024 in Journal of Dermatology and Dermatologic Surgery
Background: Vaccines against human papillomaviruses (HPVs) can prevent infection and lower the risk of cervical cancer in women. Purpose: The purpose of the study was to assess parents’ awareness level and hesitancy toward HPV vaccination of their children. Methods: This cross-sectional study recruited Saudi parents who visited Maternity and Children Hospitals, Makkah, Saudi Arabia. Results: A total of 591 parents were enrolled. About 49% of the parents have not heard about HPV before. Only 34% and 39.4% knew that HPV causes cervical cancer and that vaccination protects against cervical cancer, respectively. About one-third (30.3%) reported that they knew that HPV vaccine can be offered to female children 9 years old and above, and 80.2% had poor awareness level of the HPV. For those not planning to give their children the vaccination, the most reported reasons included lack of knowledge about the vaccine (40.7%) and not being recommended by medical staff (17.3%). The most reported source of information was social media (21.3%). Only 7% of parents vaccinated their children, and 55% planned to do so. Poor awareness was significantly associated with older age ( P = 0.001), fathers ( P = 0.002), having partially vaccinated children ( P = 0.001), and the internet as an information source ( P = 0.001). Conclusion: The parents’ awareness level is poor regarding HPV infection and vaccination. The rate of children’s vaccination is very low. The identified causes of hesitancy should be targeted in future projects to increase vaccine coverage. Social media and the Internet can be utilized to disseminate reliable information about HPV and its vaccine to a large group of audience.
1 June 2025 in International Medical Case Reports Journal
Herpes zoster infection, commonly known as shingles, typically involves the thoracic and lumbar dermatomes. Sacral involvement is rare, occurring in only 4– 8% of cases. This report presents a 55-year-old female with herpes zoster affecting the S1 dermatome, manifesting as burning pain and clustered vesicles on her right leg, without motor dysfunction or urinary symptoms. A clinical diagnosis was made based on a characteristic unilateral S1 dermatomal vesicular eruption. Despite the rarity of sacral herpes zoster without motor involvement, the patient responded well to antiviral treatment and neuropathic pain management, with no complications noted in the long-term follow-up. This case highlights the necessity for clinicians to consider sacral herpes zoster in patients with radicular pain to prevent misdiagnosis.
Background Primary care physicians (PCPs) should have adequate skills to manage common skin conditions, such as eczema, psoriasis, and vitiligo, and reduce the rate of referrals to dermatologists. Objective The aim of this study was to assess PCPs’ knowledge in diagnosing and managing common dermatological conditions. Methods This cross-sectional survey study involved PCPs in Saudi Arabia. The questionnaire consisted of three sections: demographic information, case scenarios, and questions assessing the ability to manage skin conditions. Knowledge scores were calculated by assigning one point for each correct answer. Participants rated their perceived ability on a Likert scale, ranging from 1 (totally disagree) to 5 (totally agree). Results Diagnostic accuracy was generally high, with between 61.5% and 89.8% of respondents correctly identifying the presented cases. However, only about 50% had effective knowledge of tinea corporis, seborrheic keratosis, acute urticaria, and tinea capitis. Higher knowledge levels correlated with older age (p<0.001), being a consultant or specialist (p<0.001), and working in primary healthcare (p<0.001). While 63.2% felt confident in managing common skin conditions, this confidence correlated weakly with overall knowledge (rho = 0.261, p = 0.002). Additionally, over 90% of PCPs agreed to refer difficult cases. Conclusions The knowledge of PCPs in the management of common skin conditions showed several serious deficiencies, leading to unnecessary referrals to dermatologists. There is a need for specific dermatology training programs for PCPs. Dermatology courses in medical school curricula should focus on preparing students to manage common skin conditions.
14 August 2025 in Indian Dermatology Online Journal
Background: Recently, vitamin D3 and its analogs have shown therapeutic potential in the treatment of alopecia areata (AA). Aim and Objective: The aim of this study was to evaluate the safety/efficacy of topical/intralesional vitamin D3 and its analogs for treatment of mild-to-moderate AA. Materials and Methods: We included clinical trials that evaluated topical/intralesional vitamin D3 and its analogs for the treatment of AA. Response rates were defined as either achieving a Score 4 (S4) response on the hair regrowth scale (≥75% regrowth) or reduction in the mean Severity of Alopecia Tool (SALT) score after treatment. Results: The overall success rate of vitamin D3 and its analogs in the treatment of mild-to-moderate AA is about 53.75%. Both intralesional and topical vitamin D3 (odds ratio = 3.20; 95% confidence interval (CI): [1.24, 8.24] and mean difference (MD) = 2.11; 95% CI: [-1.10, 5.31], respectively) are effective in the treatment of mild-to-moderate AA. Additionally, topical vitamin D3 analogs had a synergistic effect when used in combination with other treatments including topical corticosteroids and NB-UVB (MD = 0.62; 95% CI: [-0.24, 1.48] and MD = 1.34; 95% CI: [0.96, 1.71]), respectively. Intralesional vitamin D3 showed lower efficacy compared to intralesional corticosteroid and topical bimatoprost (MD = -4.73; 95% CI: [-7.38, -2.08]). No serious adverse events were associated with the use of vitamin D3 and its analogs. Limitations: Small number of randomized clinical trials, lack of baseline vitamin D3 levels and co-morbid autoimmune conditions assessment. Conclusion: Vitamin D3 and its analogs may serve as a safe, inexpensive alternative for mild-to-moderate patchy AA, either as a mono-therapeutic agent or as an adjuvant for more severe cases.
Bier's spots are rare angiospastic macules often associated with physiologic vasoconstriction. This case report describes a 35-year-old man with chronic myeloid leukemia treated with nilotinib who developed Bier's spots, a previously unreported adverse effect of the drug. The patient presented with asymptomatic hypopigmented macules on the hands and legs that appeared during venous stasis and resolved with elevation. This case emphasizes the need to recognize potential vascular side effects of tyrosine kinase inhibitors and highlights Bier's spots as a benign but remarkable manifestation in patients undergoing nilotinib therapy.